Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak

After a 70% slide from its peak, Novo Nordisk has been handed a rare downgrade to sell by Deutsche Bank. The move stands out because, despite the Danish drugmaker’s struggles, most Wall Street analysts have remained reluctant to advise clients to exit the stock. This shift in tone marks a meaningful change in sentiment for a company once seen as the dominant player in the booming weight-loss and diabetes drug market.

For market observers, the downgrade highlights how expectations for pharmaceutical names can shift rapidly. A sell rating from a major bank typically signals concerns about future earnings visibility, intensifying competition, or slowing product uptake. In Novo Nordisk’s case, investors have increasingly focused on the long-term durability of its GLP-1 franchise, the potential for newer rivals, and the sustainability of pricing power.

Looking ahead, the key question is whether other banks will follow Deutsche Bank’s lead or continue to hold more constructive views. Clarity may come from upcoming clinical data, regulatory milestones, and quarterly sales reports. Until those inputs arrive, the stock’s direction will likely remain sensitive to any tweaks in analyst sentiment.